Citius Pharmaceuticals, Inc.
CTXR
$0.56
-$0.03-5.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -158.26% | -3.29% | 9.45% | 19.48% | -11.76% |
| Total Depreciation and Amortization | 216.16% | 798.39% | 49.76% | -26.07% | 2.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -193.63% | 48.05% | -6.76% | 8.38% | 4.18% |
| Change in Net Operating Assets | 341.68% | -39.39% | -926.40% | -80.45% | 45.66% |
| Cash from Operations | 90.01% | -9.49% | -119.75% | -19.10% | 3.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 86.36% | 23.48% | -- | -- | -- |
| Cash from Investing | 86.36% | 23.48% | -- | -- | -- |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | 32.19% | 50.86% | 202.07% | 34.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | 0.00% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -105.90% | 32.19% | 37.71% | 230.93% | 34.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -190.26% | 288.87% | -130.30% | 664.65% | 50.10% |